Kristina Tatiossian, PhD, founder of Arkitekt Agency, looks at how biotech companies are currently using social media and provides a five-step guide for how to make the most of this ubiquitous marketing tool. Biotechnology organisations can leverage social media for a variety of purposes, from boosting awareness and increasing engagement,… Read More
DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year. The Market After over two years of the Covid-19 pandemic, 2022 year was somewhat of a return to… Read More
WuXi STA, a subsidiary of WuXi AppTec, has received scores of 60+ with a Silver rating from EcoVadis, a provider of business sustainability ratings, for its three sites in China. The scores were received for active pharmaceutical ingredients (API) R&D and manufacturing from the Changzhou site, and… Read More
GSK has announced strong quarterly results, reporting sales of £7.8 billion and growth in various sectors of the business. Overall, the company’s adjusted operating profit for the third quarter came in at £2.6 billion, a 17% increase compared to the same period last year and reflecting a… Read More
Clinical-stage company Respira Technologies has appointed a new Chief Executive Officer (CEO) to the company. Brian Quigley will take over as CEO after working as Respira’s Chief Operating Officer (COO) for the past two years. Quigley previously worked at Altria Group for 16 years where… Read More
Artificial intelligence (AI) company Atomwise has signed an exclusive research collaboration with Sanofi to use its AtomNet platform for computational discovery and research of up to five drug targets. The agreement will see Atomwise receive $20 million from Sanofi to identify, synthesise, and advance lead compounds for… Read More
Clinical-stage drug discovery company Ryvu Therapeutics has received €22 million from the European Investment Bank (EIB) to help it advance its portfolio of cancer treatments. The funding, which is being provided under the EIB’s venture debt instrument, will help Ryvu finance its development pipeline of new cancer… Read More
News round-up by DDW’s Reece Armstrong for 8-12 August New insights into melanoma, a company transition into life sciences and a Lyme disease vaccine are some of the stories in this week’s news round-up. Pfizer launches Phase III trial for Lyme disease vaccine Pfizer… Read More
Life sciences company PerkinElmer will divest its Applied, Food and Enterprise Services to the private equity firm New Mountain Capital in a potential deal worth $2.45 billion. PerkinElmer states that the deal comes at a pivotal moment for the company as it transitions to solely focusing on its Life… Read More
Life sciences property provider Bruntwood SciTech has invested £20 million into redeveloped laboratories at the UK’s North West research campus, Alderley Park. The £20 million investment has gone towards the redevelopment of existing lab spaces to create high-specification biology and chemistry containment level two (CL2) laboratory suites. Read More
Techbio company Closed Loop Medicines has appointed two new members in support of its planned international growth. Closed Loop Medicines appointed David Van Sickle as Non-Executive Director and Simon Ramsden as Chief Financial Officer. Closed Loop Medicine says that the hires will help in the… Read More
A UK centre for synthetic biology has received £5.5 million in funding so it can support start-ups and SMEs in the sector. The UK’s National Centre for the Industrial Translation of Synthetic Biology, SynbiCITE, will use the funding to support businesses within the sector and to help… Read More
Precision medicine start-up Vesynta has become the first medtech company to move into a laboratory at south London’s latest incubator space. The company, which was spun out from the Adaptive and Responsive Nanomaterials group at University College London, has moved into the Innovation Gateway at The London Cancer… Read More
Organ-on-a-chip Company (OOC) CN Bio has expanded its contract research services with the opening of new laboratory facilities at Cambridge Science Park, in the UK. The company has double its laboratory space in response to the increasing demand for OOC services as seen throughout drug discovery and development programmes. Read More
Biotechnology company Complement Therapeutics has appointed a new member to its board to help support the company with its development goals. Complement Therapeutics appointed Steve Axon as in independent director to its Board of Directors who will help the company with its goals of addressing unmet needs… Read More
Origin Therapeutics, an investment company focused on psychedelic therapies, has added Canadian biotech Clairvoyant to its portfolio. Clairvoyant is developing psychedelic drug therapy focused on addiction and is targeting the clinical validation of psilocybin in the EU, the UK, and Canada. The company is currently proceeding with… Read More
